Synercid, a new semisynthetic
streptogramin-derived
antibiotic containing
dalfopristin and
quinupristin, is used in treatment of life-threatening
infections caused by
glycopeptide-resistant Enterococcus faecium and other bacterial pathogens. However, dissemination of genes encoding
virginiamycin acetyltransferases,
enzymes that confer resistance to
streptogramins, threatens to limit the medical utility of the
quinupristin-dalfopristin combination. Here we present structures of
virginiamycin acetyltransferase D (VatD) determined at 1.8 A resolution in the absence of
ligands, at 2.8 A resolution bound to
dalfopristin, and at 3.0 A resolution in the presence of
acetyl-coenzyme A.
Dalfopristin is bound by VatD in a similar conformation to that described previously for the
streptogramin virginiamycin M1. However, specific interactions with the substrate are altered as a consequence of a conformational change in the pyrollidine ring that is propagated to adjacent constituents of the
dalfopristin macrocycle. Inactivation of
dalfopristin involves acetyl transfer from
acetyl-coenzyme A to the sole (O-18) hydroxy group of the
antibiotic that lies close to the side chain of the strictly conserved residue, His-82. Replacement of residue 82 by
alanine is accompanied by a fall in specific activity of >105-fold, indicating that the
imidazole moiety of His-82 is a major determinant of catalytic rate enhancement by VatD. The structure of the VatD-
dalfopristin complex can be used to predict positions where further structural modification of the
drug might preclude
enzyme binding and thereby circumvent
Synercid resistance.